Goldman Sachs Group Inc Citius Pharmaceuticals, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTXR
# of Institutions
70Shares Held
30.6MCall Options Held
24.7KPut Options Held
0-
Armistice Capital, LLC New York, NY10.2MShares$3.55 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$2.21 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$717,1010.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$632,0040.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.65MShares$576,2030.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $51.1M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...